Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 December 30, 2025
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial of bexmarilimab + zimberelimab December 30, 2025
First Patient Dosed in Ph 3 ALPACCA Trial of Firmonertinib in 1L EGFR PACC Mutant NSCLC December 30, 2025
FAILED TRIAL: LATIFY Ph 3 trial of ceralasertib + Imfinzi did not meet the OS primary endpoint vs SOC docetaxel in NSCLC patients December 30, 2025
US FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and LAZCLUZE® (lazertinib) combo for 1L EGFRm NSCLC December 22, 2025
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline Including OMNI-EGFR Inhibitor for NSCLC December 15, 2025
Immutep and Dr. Reddy’s enter Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 15, 2025
New Analyses of DUBLIN-3 Ph 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for NonSq EGFR WT NSCLC and a Reduction in Brain Mets Compared to Docetaxel Announced December 15, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant OS improvement for Asian patients with EGFR-mutated NSCLC in the Ph 3 MARIPOSA study December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
First-in-Human Data from Ph 1 Trial of GTA182 in MTAP-Deleted Advanced NSCLC presented December 9, 2025
Clinically Meaningful OS Benefit for Gotistobart in Patients with Previously Treated Squamous NSCLC Announced December 9, 2025
Preliminary Ph 2 Data for Silevertinib in 1L NSCLC and Plans for Ph 2 Trial of Silevertinib in GBM Announced December 9, 2025
Ph 3 Trial of Sac-TMT in Combination with KEYTRUDA as 1L Treatment for PD-L1-Positive NSCLC Met Primary Endpoint December 2, 2025
Clinical results of glecirasib in combination with JAB-3312 (sitneprotafib) in KRAS G12C–mutated NSCLC published in The Lancet Respiratory Medicine December 2, 2025
HREC provides human ethics approval for HARNESS-1 Ph 1a/b trial of RC220 in patients with EGFR-mutated NSCLC December 2, 2025
FDA grants accelerated approval to HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant NSCLC November 24, 2025
Positive Recommendation from IDMC to Continue Pivotal Ph 3 ARTEMIA Trial Evaluating Tedopi® in NSCLC November 24, 2025
FDA Accepts NDA for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC November 24, 2025
Rolling Submission of NDA to FDA initiated for Zipalertinib for Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations November 24, 2025
